Theradaptive Strengthens Leadership with Jeffrey W. Dunn's Board Appointment

Theradaptive, a leading clinical-stage biologic company that focuses on targeted protein therapeutics, has made a significant move by appointing Jeffrey W. Dunn to its Board of Directors. This decision brings a wealth of knowledge and rich experience to the company's leadership, as Dunn boasts over thirty years in the medical device, biotechnology, and technology sectors.

Who is Jeffrey W. Dunn?

Jeffrey Dunn co-founded SI-BONE, Inc. in 2008, a notable company specializing in musculoskeletal medical devices. Under his guidance, SI-BONE penetrated the public market with a successful IPO, achieving a market capitalization of over $1 billion. His illustrious career is accentuated by his leadership in founding and leading several companies, including INBONE Technologies and Accelgraphis, in addition to serving as CEO for Active Decisions, Velogic, and EnterpriseLink Technology Corp.

Dunn has a proven ability to enhance shareholder value and has been instrumental in raising substantial funds to fuel business growth. His expertise spans various crucial aspects of corporate development, including mergers and acquisitions. Notably, he has successfully directed high-profile exits such as the sale of INBONE Technologies to Wright Medical Technology and multiple strategic acquisitions that propelled the companies involved to new heights.

A Vision for the Future

Luis Alvarez, CEO of Theradaptive, expressed that the board is delighted to have Dunn on board. His immense industry acumen and strategic foresight are seen as crucial elements in propelling the company towards its commercial launch. Alvarez emphasized how Dunn recognized the unparalleled value proposition at Theradaptive, which combines the lucrative potential of biopharma with the low capital requirements characteristic of medtech.

Dunn himself shared his enthusiasm about joining Theradaptive, highlighting the company's innovative approaches in regenerative medicine and targeted therapeutics. He stated, “Theradaptive's pioneering work aligns perfectly with my passion for advancing healthcare innovation. The company has a tremendous opportunity to disrupt the $4 billion bone graft market, positioning itself as a leader while reducing healthcare costs.” Dunn’s commitment underscores the potential for creating advanced treatment pathways that can enhance patient access and deliver significant returns for investors.

Theradaptive's Journey

Founded in 2017 and based in Frederick, Maryland, Theradaptive is at the forefront of protein engineering technologies that facilitate targeted and efficient drug delivery, geared towards multi-indication tissue regeneration and therapeutics. The inclusion of Dunn on its Board is a testament to Theradaptive’s strategy of solidifying its executive capabilities as it aims to heighten its influence within the biotechnology sphere.

About Theradaptive
Theradaptive specializes in developing innovative protein therapeutics aimed at spine, orthopedics, dental, and soft tissue repair applications. The company's platform is built to deliver recombinant biologics with precision and persistence to address unmet medical needs effectively. For more information about Theradaptive's mission and clinical advancements, please visit www.theradaptive.com and connect with them on LinkedIn. It's essential to note that OsteoAdapt™ SP is an Investigational Device, limited by U.S. Federal law to investigational use.

Conclusion

The appointment of Jeffrey W. Dunn to the board of Theradaptive marks a pivotal moment for the company as it seeks to enhance its strategic direction and drive innovation in the realm of targeted therapeutics. With Dunn’s extensive experience and vision, Theradaptive is set to make substantial strides in transforming the healthcare landscape.